CD19 and diffuse large B-cell lymphoma: In October 2017, axicabtagene ciloleucel (axi-cel) became the first CD19-targeted CAR-T approved by the Food and Drug Administration (FDA) as third- (3 L) or subsequent-line (+) therapy for R/R DLBCL based on the results of the ZUMA-1 clinical trial [13, 14].